#USA #Cambridge #MetaVia #DA-1241 #EASL Congress

MetaVia Inc. Set to Showcase Late-Breaking Data at EASL Congress 2025

MetaVia Inc., a pioneering biotechnology company focused on cardiometabolic disease treatment, has made an exciting announcement revealing its participation at the upcoming European Association for the Study of the Liver (EASL) Congress 2025. The congress is scheduled to take place from May 7 to May 10, 2025, in Amsterdam, Netherlands. During this highly anticipated event, MetaVia will present compelling findings from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist.

The presentation is especially noteworthy as it includes late-breaking data that will be discussed in a poster session. The abstract, titled "DA-1241, a GPR119 Agonist, Demonstrates Hepatoprotective and Glucose-Regulating Effects in a 16-week Randomized Placebo-Controlled Trial in Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients," has been recognized for its significance and scientific merit. It will be presented by Dr. Rohit Loomba, a distinguished Professor of Medicine at the University of California, San Diego.

Details of the Presentation

The presentation will occur on May 7, 2025, at 8:30 AM CET, and is categorized under session LB2517, which focuses on late-breaking posters. Participants are encouraged to review the findings which will be accessible on MetaVia's website following the presentation.

Understanding DA-1241

DA-1241 is an innovative GPR119 agonist that holds promise as both a standalone therapy and in combination with other treatments for metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes (T2D). As a GPR119 agonist, it functions by stimulating the release of essential gut hormones such as GLP-1, GIP, and PYY, which play critical roles in regulating glucose and lipid metabolism, and promoting weight loss.

The clinical and preclinical research surrounding DA-1241 has indicated its efficacy in improving liver inflammation, glucose profiles, and overall metabolic health. In preclinical studies, this compound has shown a significant decrease in hepatic steatosis, inflammation, and fibrosis while effectively enhancing glucose control in various models of MASH and T2D.

In earlier phases of clinical trials (Phases 1a, 1b, and 2a), DA-1241 was well tolerated among participants, demonstrating its potential safety and tolerability profile. The latest Phase 2a trial results suggest that DA-1241 not only acts on metabolic pathways but also directly impacts liver metabolism, boosting its therapeutic value in treating patients with MASH and T2D.

About MetaVia Inc.

Founded to target unmet needs in cardiometabolic health, MetaVia Inc. is at the forefront of innovative therapies that aim to improve patients' quality of life. In addition to its work on DA-1241, the company is also advancing the development of DA-1726, a dual agonist designed to facilitate weight loss and improve metabolic function.

For more detailed information about MetaVia and its research initiatives, please visit www.metaviatx.com.

This EASL Congress presentation promises to provide groundbreaking insights into the future of treating metabolic diseases, and it highlights MetaVia's commitment to enhancing therapeutic options available to patients worldwide.